10th International Oncolytic Virus Meeting, Vancouver, 2016

Agenda

Saturday, October 1st (afternoon & evening)
- Registration Open
- Welcome reception and Keynote Talks
  - Cassian Yee: Adoptive T cell therapy (ACT)
  - Yonghong Wan: Combining ACT and OV

Sunday, October 2nd (morning)
- Breakfast
- Session 1: Viral Engineering and Replication
  - Chairs: David Stojdl/Len Seymour
  20min Talk:
  Abstract #123: STRATEGIES TO ENHANCE BOTH ONCOLOYTIC ACTIVITY AND SAFETY SIMULTANEOUSLY FOR ONCOLOYTIC VIROTHERAPY – William Jia (UBC)

15min talks:
Abstract #87: Development of immunogenic BHV-1 to target non-inflamed tumors – Karen Mossman (McMaster University)

Abstract #59: A genome wide lentiviral CRISPR screen identifies genes & pathways that underlie resistance to oncolytic virus infection & killing - Larissa Pikor (Ottawa Hospital Research Institute)

Abstract #37: Oncolytic viruses targeting the RNAi pathway - Amelia Aitken (Ottawa Hospital Research Institute)

Abstract #96: Novel oHSV vectors designed to evade the innate immune system show increased therapeutic efficacy in glioblastoma mouse models - Korneel Grauwet (Harvard Medical School)

Abstract #117: Next Generation Oncolytic Vaccinia Viruses – Andrea McCart (U of Toronto)

Abstract #62: Characterizing the host mRNAs actively translated during viral oncolysis - Huy-Dung Hoang (CHEO Research Institute, University of Ottawa)

Abstract #78: Random mutagenesis of Vaccinia virus uncovers novel clinical candidate oncolytic backbones with unique phenotypes - Brian Keller (OHRI)
Sunday, October 2\textsuperscript{nd} (afternoon)

- Session 2: Oncolytic viruses and Immunity A
  - Chairs: Brian Lichty/Nino Chiocca

20min talks:
- Steve Thorne: TBA
- Brian Lichty: TBA
- Nino Chiocca: TBA

15min talks:
  Abstract #53: Immune cell recruitment and anti-tumor IgG responses following intrapleural administration of oHSV Seprehvir in patients with mesothelioma - Joe Conner (Virttu Biologics)

  Abstract #66: Oncolytic virus-mediated immunotherapy - Marie-Claude Bourgeois-Daigneault (Ottawa Hospital Research Institute)

  Abstract #44: Oncolytic adenovirus coated with MHC I–restricted peptides for simultaneous targeting of several (neo-) antigens to counteract tumor immune escape - Siri Tähtinen (University of Helsinki)

  Abstract #101: Complete remission of breast cancer tumors in an immune competent mouse model using measles and VSV-measles chimeric viruses - Christopher Richardson (Dalhousie University)

_____________

Sunday, October 2\textsuperscript{nd} (evening)

- Working Dinner
- Session 3: Combination Therapies A
  - Chairs: Jean-Simon Diallo/Caroline Breitbach

20min talks:
Nori Kasahari (Miami) - TBA
Kay-Whye Peng (Mayo Clinic) - TBA

  Abstract #65: Post-treatment Chemotherapy Enhances Oncolytic Recombinant Poliovirus Efficacy - Jeffrey Bryant (Duke)

  Abstract #127: Enhancing Therapeutic Efficacy of an Oncolytic Virus with a $\beta1$ Integrin Blocking Antibody, OS2966 - Ji Young Yoo (Ohio State)

  Abstract #27: Oncolytic adenoviruses armed with tumor necrosis factor alpha and interleukin-2 enable successful adoptive cell therapy of solid tumors - Mikko Siurala (TILT, Helsinki)

Poster Session #1
Monday, October 3rd (morning)
  • Breakfast
  • Session 4: Delivery, Imaging and Toxicology:
    - Chairs: Grant McFadden/ Len Seymour

20min talks:
- Grant McFadden – Ex Vivo Virotherapy with Myxoma Virus
- Aladar Szalay - TBA

15min talks:
Abstract #121: Pig as an in vivo model to assess performance of tropism-modified oncolytic adenoviruses: Julia Davydova (University of Minnesota)

Abstract #113: Preclinical study for tumor-targeted and armed oncolytic vaccinia virus for systemic cancer virotherapy - Takafumi Nakamura (Totorri University)

Debate: Intratumoral Delivery versus Systemic Delivery
Rob Coffin (Replimune) for IT and Kerry Fisher (U of Oxford) for IV

Monday, October 3rd (afternoon)
  • Session 5: Oncolytic viruses and Immunity B
    - Chairs: Alan Melcher/Brian Lichty

20min talks:
- Alan Melcher: TBA
- Liz Ilett: TBA

15min talks:
Abstract #29: Determinants of efficacy in virotherapy - Ruta Veinalde (NCT Heidelberg)

Abstract #33: OV sensitize tumor cells for NYESO-1 recognition - Tiphaine Delaunay (INSERM)

Abstract #92: Blockade of PD-1 or TIM3 on Acutely Expanding CD8+ Effector T Cell Populations Following VSV Virotherapy Has Minimal Effects on Enhancing Therapy - Richard Vile (Mayo Clinic)

Abstract #82: Arming a HSV-2- based oncolytic virus with the ability to re-direct hosts innate immune cells to attack tumor cells - Shaun Xiaoliu Zhang (University of Houston)
Abstract #90: Eradication of peritoneal carcinomatosis using a Maraba virus infected cell vaccine expressing IL-12 requires recruitment of Natural Killer cells - Almohanad Alkayyal (Ottawa Hospital Research Institute)

Monday, October 3rd (evening)
- Working Dinner
- Session 6: Tumour Microenvironment
  - Chairs: Martine Lamfers/John Bell

20min talks:
John Bell - TBA

Oncolytic viral therapy with Delta24-RGD can induce tumor-detrimental environment via phenotypic shift of macrophages - Wouter van den Bossche (Dep of Neurosurgery/ Dep of Immunology, Erasmus MC)

15min talks

Abstract #142: Oncolytic adenovirus targeting tumour cells and stromal components - Joshua Freedman (U of Oxford)

Abstract #30: Predictive gene expression signature for personalized medicine – Amber Miller (May Clinic)

Abstract #72: Phase II CALM Extension study: Intratumoral Coxsackievirus A21 increases immune-cell infiltrates and up-regulates immune-checkpoint molecules in the microenvironment - Darren Shafren (Viralytics)

Poster Session #2

Tuesday, October 4th (morning)
- Breakfast
- Session 7: Combination Therapies B
- Chairs: Kah-Whye Peng/Nori Kasahari

20 min talk:
Jean-Simon Diallo (Ottawa Hospital Research Institute) - TBA

15 min talks:
Abstract #74: Multiple Mechanisms of Oncolytic Herpes Simplex Virus and Aurora A Kinase Inhibition in Models of Neuroblastoma and Malignant Peripheral Nerve Sheath - Leslee Sprague (Ohio State)

Abstract #135: Cooperation Between Endogenous Lymphocytes and ACT - Boris Simovic (McMaster University)

Abstract #126: MEK kinase inhibitor, Trametinib, Suppresses Macrophage-Secreted TNF-a on Oncolytic HSV-1 Therapy, Enhancing Virotherapy - Ji Young Yoo (Ohio State)

Abstract #73: Viro-immunotherapy with oncolytic H-1 parvovirus in combination with bevaciciumab and PD-1 checkpoint blockade leads to rapid anti-tumor response in th ??? – Karsten Galetneky (Klinikum Darmstadt)

Tuesday, October 4th (afternoon)
• Session 8: Clinical Trials
  - Chairs: Robert Coffin/Steven Russell

20min Talks:
Abstract #40: Updated phase 1b analysis of MASTERKEY-265, a phase 1b/3 study of talimogene laherparepvec and pembrolizumab for unresectable stage IIIB-IV melanoma - Robert H.I. Andtbacka - (Huntsman Cancer Institute, University of Utah)

- Steven Russell - TBA

Abstract #120: A Phase 2 trial to evaluate efficacy and safety of HF10 oncolytic virus immunotherapy and ipi in pts with unresectable or metastatic melanoma - Robert H.I. Andtbacka – (Huntsman Cancer Institute, University of Utah)

15 min talks:
Abstract #51 Oncolytic H-1 parvovirus shows safety and surrogate efficacy in a phase I/IIa clinical trial (ParvOryx01) for recurrent glioblastoma patients - Jean Rommelaere (Deutsches Krebsforschungszentrum, Heidelberg)

Abstract #71 Molecular Analyses and Immune Activity of Toca 511 a Retroviral Replicating Vector in Preclinical Models and Three Ascending Dose Trials in Patients w - Douglas Jolly (Tocagen Inc.)
Abstract #89 Phase I/II CANON study: Oncolytic immunotherapy for the treatment of Non-Muscle Invasive Bladder (NMIBC) Cancer using Intravesical Coxsackievirus A21 - Hardev Pandha (U of Surrey)

Abstract #102 Phase 1 Study of ITu Seprehvir (oHSV) in Children and Young Adults Demonstrates Safety and Induces Both an Inflammatory Reaction and Delayed Viremia - Keri Streby (Nationwide Children’s Hospital)

Tuesday, October 4th (evening)
- Reception
- Banquet